Alaya.bio
Alaya is a preclinical in vivo CAR-T developer. Its disclosed polymeric nanoparticle platform encapsulates lentiviral CAR vectors for targeted T-cell transduction; this is a hybrid polymer/viral approach, not simply a nonviral polymer delivery system.
Corporate information
- Company entity
- Alaya.bio
- Headquarters / principal office
- New York City, United States; R&D in Villejuif, France ↗
- Founded
- 2022 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.alaya.bio/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Alaya is a preclinical in vivo CAR-T developer. Its disclosed polymeric nanoparticle platform encapsulates lentiviral CAR vectors for targeted T-cell transduction; this is a hybrid polymer/viral approach, not simply a nonviral polymer delivery system.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.